lobbying_activities: 3391836

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
3391836	444f7fea-eeff-45b0-811d-17fcedd3d592	Q2	DLA PIPER LLP (US)	76855	NOVARTIS	2025	second_quarter	PHA	Issues relating to drug pricing policy. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act.	Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE	40000		0	0	2025-07-18T10:00:45-04:00